Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 24-07-03 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24-04-24 | Antibe Announces Appointment of Receiver | BU |
| 24-04-22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 24-04-19 | Antibe Provides Update on CCAA Proceedings | BU |
| 24-04-16 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 2015-11-30 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/8/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 3/8/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 3/8/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +0.41% | -2.07% | +41.26% | +95.40% | 68.87B | |
| +1.31% | +0.55% | +49.48% | +90.80% | 65.29B | |
| +0.04% | +4.36% | -11.72% | +459.54% | 27.65B | |
| +2.97% | +0.40% | +38.60% | +14.84% | 25.77B | |
| -0.90% | -7.65% | +2.45% | -15.50% | 26.08B | |
| +1.01% | +1.38% | +26.48% | -17.16% | 20.14B | |
| +3.45% | -13.46% | +222.69% | +389.50% | 17.03B | |
| +0.77% | -5.28% | -3.25% | +549.41% | 15.03B | |
| +1.03% | +7.00% | +59.98% | +160.03% | 14.5B | |
| Average | +1.01% | -1.83% | +47.33% | +191.87% | 31.15B | |
| Weighted average by Cap. | +0.98% | -1.19% | +42.63% | +149.98% |
Employees
11
